PE20050193A1 - Compuestos heterociclicos utiles como activadores de nurr-1 - Google Patents
Compuestos heterociclicos utiles como activadores de nurr-1Info
- Publication number
- PE20050193A1 PE20050193A1 PE2004000155A PE2004000155A PE20050193A1 PE 20050193 A1 PE20050193 A1 PE 20050193A1 PE 2004000155 A PE2004000155 A PE 2004000155A PE 2004000155 A PE2004000155 A PE 2004000155A PE 20050193 A1 PE20050193 A1 PE 20050193A1
- Authority
- PE
- Peru
- Prior art keywords
- alcoxy
- hydroxy
- compounds
- nurr
- activators
- Prior art date
Links
- 239000012190 activator Substances 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 4
- -1 BENZYLOXY Chemical class 0.000 abstract 2
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 229910052801 chlorine Chemical group 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 102000006255 nuclear receptors Human genes 0.000 abstract 1
- 108020004017 nuclear receptors Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA (I), DONDE R1 ES HIDROXI, ALCOXI(C1-C4), AMINO, ALQUILAMINO(C1-C4), DIALQUILAMINO(C1-C4), BENCILOXI O ALCANOILO(C2-C7); R2 ES ALQUILO(C1-C4), ALCOXI(C1-C4), ALCOXI(C1-C4)-ALCOXI(C1-C4), CF3, HALOGENO, ALQUILAMINO(C1-C4), DIALQUILAMINO(C1-C4), DIALQUILAMINO(C1-C4)-ALCOXI(C1-C4), ENTRE OTROS; X ES N U O; Y ES N, O o CH; Z ES N O CH Y W ES N O CH SIEMPRE QUE: a) R1 NO SEA HIDROXI O ALCOXI(C1-C4) CUANDO R2 SEA CF3, X SEA O, Y SEA CH, Z SEA N Y W SEA CH, b) R1 NO SEA HIDROXI O ALCOXI(C1-C4) CUANDO R2 ES CF3 O CLORO, X ES N, Y ES O, Z ES CH Y W ES CH, c) R1 NO SEA HIDROXI CUANDRO R2 SEA CF3, X SEA O, Y SEA N, Z SEA CH, Y W SEA CH Y d) X E Y SIMULTANEAMENTE NO SEAN O. SON COMPUESTOS PREFERIDOS: ACIDO 3-[3-(4-TRIFLUOROMETIL-FENIL)-[1,2,4]OXADIAZOLES-5-IL]-BENZOICO, ACIDO 3-[3-(6-DIMETILAMINO-PIRIDIN-3-IL)-[1,2,4]OXADIAZOL-5-IL]-BENZOICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION DE ESTOS COMPUESTOS Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE. ESTOS COMPUESTOS SON ACTIVADORES DE LOS RECEPTORES NUCLEARES Nurr 1 Y PUEDEN SER UTILES PARA PREVENIR O RETRASAR EL INICIO DE SINTOMAS DE LA ENFERMEDAD DE PARKISON
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0303503.7A GB0303503D0 (en) | 2003-02-14 | 2003-02-14 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050193A1 true PE20050193A1 (es) | 2005-04-11 |
Family
ID=9953078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000155A PE20050193A1 (es) | 2003-02-14 | 2004-02-12 | Compuestos heterociclicos utiles como activadores de nurr-1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7432293B2 (es) |
| EP (1) | EP1597243A1 (es) |
| JP (1) | JP2006517564A (es) |
| CN (2) | CN100475795C (es) |
| AR (1) | AR043168A1 (es) |
| AU (1) | AU2004212151B2 (es) |
| BR (1) | BRPI0407479A (es) |
| CA (1) | CA2515847A1 (es) |
| GB (1) | GB0303503D0 (es) |
| MX (1) | MXPA05008584A (es) |
| PE (1) | PE20050193A1 (es) |
| PL (1) | PL376754A1 (es) |
| TW (1) | TW200502225A (es) |
| WO (1) | WO2004072050A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE047569T2 (hu) | 2003-04-11 | 2020-04-28 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása |
| WO2006044502A2 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| WO2006110483A1 (en) | 2005-04-08 | 2006-10-19 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| JP2008539195A (ja) | 2005-04-26 | 2008-11-13 | ノイロサーチ アクティーゼルスカブ | 新規のオキサジアゾール誘導体及びそれらの医学的使用 |
| US9289398B2 (en) | 2006-03-30 | 2016-03-22 | Ptc Therapeutics, Inc. | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith |
| FR2903108B1 (fr) * | 2006-07-03 | 2008-08-29 | Sanofi Aventis Sa | Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique. |
| FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2903105A1 (fr) | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
| ES2404348T3 (es) | 2006-09-08 | 2013-05-27 | Ptc Therapeutics, Inc. | Procedimiento para la preparación de ácidos 1, 2, 4-oxadiazol-benzoicos |
| FR2906250B1 (fr) * | 2006-09-22 | 2008-10-31 | Sanofi Aventis Sa | Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique |
| PT2076501E (pt) | 2006-09-25 | 2016-03-31 | Ptc Therapeutics Inc | Formas cristalinas do ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzóico |
| EP2068871B1 (en) | 2006-09-25 | 2013-12-25 | PTC Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression |
| BR122019020961B8 (pt) * | 2006-10-12 | 2021-07-27 | Ptc Therapeutics Inc | uso do ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzóico ou um sal farmaceuticamente aceitável do mesmo |
| EP2182809B1 (en) | 2007-08-27 | 2018-01-17 | Dart Neuroscience (Cayman) Ltd | Therapeutic isoxazole compounds |
| BRPI0913609B8 (pt) | 2008-06-09 | 2021-05-25 | Univ Muenchen Ludwig Maximilians | composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit |
| CN102076670B (zh) * | 2008-06-24 | 2013-05-22 | Irm责任有限公司 | 调节g蛋白偶联受体的化合物和方法 |
| FR2933609B1 (fr) | 2008-07-10 | 2010-08-27 | Fournier Lab Sa | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson. |
| WO2011009484A1 (en) * | 2009-07-22 | 2011-01-27 | Novartis Ag | Arylpyrazoles and arylisoxazoles and their use as pkd modulators |
| FR2950053B1 (fr) | 2009-09-11 | 2014-08-01 | Fournier Lab Sa | Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
| FR2955110A1 (fr) * | 2010-01-08 | 2011-07-15 | Fournier Lab Sa | Nouveaux derives de type pyrrolopyridine benzoique |
| MX2013004176A (es) * | 2010-10-14 | 2013-10-25 | Daiichi Sankyo Co Ltd | Derivado de acilbenceno. |
| EP3066083B1 (de) | 2013-11-05 | 2019-10-30 | Bayer Animal Health GmbH | Neue verbindungen zur bekämpfung von arthropoden |
| CN106455571A (zh) | 2014-03-06 | 2017-02-22 | Ptc医疗公司 | 1,2,4‑噁二唑苯甲酸的药物组合物和盐 |
| WO2017075312A1 (en) | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
| US11180518B2 (en) | 2017-05-12 | 2021-11-23 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04295470A (ja) | 1991-03-22 | 1992-10-20 | Wakamoto Pharmaceut Co Ltd | モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法 |
| WO1997003967A1 (en) * | 1995-07-22 | 1997-02-06 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
| DE19620041A1 (de) * | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19643037A1 (de) * | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| IT1300055B1 (it) * | 1998-04-17 | 2000-04-05 | Boehringer Ingelheim Italia | Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici |
| CN1314899A (zh) * | 1998-07-01 | 2001-09-26 | 武田药品工业株式会社 | 视黄酸类相关的受体机能调节剂 |
| JP2000080086A (ja) * | 1998-07-01 | 2000-03-21 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| ES2211420T3 (es) * | 1999-07-21 | 2004-07-16 | F. Hoffmann-La Roche Ag | Derivados de triazol. |
| EP1210344B1 (en) * | 1999-08-19 | 2005-10-19 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| ATE375340T1 (de) * | 2001-02-21 | 2007-10-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten |
| WO2003000249A1 (en) * | 2001-06-26 | 2003-01-03 | Takeda Chemical Industries, Ltd. | Function regulator for retinoid relative receptor |
-
2003
- 2003-02-14 GB GBGB0303503.7A patent/GB0303503D0/en not_active Ceased
-
2004
- 2004-02-12 PE PE2004000155A patent/PE20050193A1/es not_active Application Discontinuation
- 2004-02-12 AR ARP040100440A patent/AR043168A1/es unknown
- 2004-02-13 WO PCT/EP2004/001372 patent/WO2004072050A1/en not_active Ceased
- 2004-02-13 MX MXPA05008584A patent/MXPA05008584A/es active IP Right Grant
- 2004-02-13 AU AU2004212151A patent/AU2004212151B2/en not_active Ceased
- 2004-02-13 CN CNB2004800038107A patent/CN100475795C/zh not_active Expired - Fee Related
- 2004-02-13 PL PL376754A patent/PL376754A1/pl not_active Application Discontinuation
- 2004-02-13 JP JP2006501839A patent/JP2006517564A/ja active Pending
- 2004-02-13 CA CA002515847A patent/CA2515847A1/en not_active Abandoned
- 2004-02-13 US US10/545,245 patent/US7432293B2/en not_active Expired - Fee Related
- 2004-02-13 TW TW093103501A patent/TW200502225A/zh unknown
- 2004-02-13 BR BR0407479-3A patent/BRPI0407479A/pt not_active IP Right Cessation
- 2004-02-13 EP EP04710812A patent/EP1597243A1/en not_active Withdrawn
- 2004-02-13 CN CN200910004889A patent/CN101665469A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1597243A1 (en) | 2005-11-23 |
| MXPA05008584A (es) | 2005-11-04 |
| BRPI0407479A (pt) | 2006-02-07 |
| PL376754A1 (pl) | 2006-01-09 |
| US20060089365A1 (en) | 2006-04-27 |
| CN100475795C (zh) | 2009-04-08 |
| CA2515847A1 (en) | 2004-08-26 |
| JP2006517564A (ja) | 2006-07-27 |
| CN1747942A (zh) | 2006-03-15 |
| TW200502225A (en) | 2005-01-16 |
| US7432293B2 (en) | 2008-10-07 |
| CN101665469A (zh) | 2010-03-10 |
| AU2004212151B2 (en) | 2008-09-04 |
| AU2004212151A1 (en) | 2004-08-26 |
| AR043168A1 (es) | 2005-07-20 |
| WO2004072050A1 (en) | 2004-08-26 |
| GB0303503D0 (en) | 2003-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050193A1 (es) | Compuestos heterociclicos utiles como activadores de nurr-1 | |
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| PE20011030A1 (es) | Combinaciones farmaceuticas que comprenden tegaserod y omeprazol | |
| PE1998A1 (es) | DERIVADOS DE BENZO [g] QUINOLINA | |
| NO20050429L (no) | Substituert kinolin-CCR5-reseptorantagonister | |
| PE20040600A1 (es) | Derivados de triazol como antagonistas del receptor de taquicinina | |
| PE20040691A1 (es) | 4-piperazinilbencenosulfonilindoles afines con el receptor 5-ht6 | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| AR037682A1 (es) | Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| PE20021015A1 (es) | Compuestos inhibidores de tirosina cinasa | |
| PE20041040A1 (es) | Compuestos derivados de amidas como inhibidores de 11-beta-hidroxiesteroide-deshidroxigenasa de tipo 1 | |
| CR8530A (es) | Intermediarios de quinolona como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos | |
| PE20040512A1 (es) | Compuesto de pirazol-pirimidina anilina | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| PE20040832A1 (es) | Derivados de indolil pirazinona | |
| AR052312A1 (es) | 2- anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y medicamentos preparados en base al compuesto | |
| PE59999A1 (es) | Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos | |
| PA8581401A1 (es) | Compuestos de imedazopiridina como agonistas del receptor 5-ht4 | |
| PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
| PE20050465A1 (es) | Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
| BR0104834A (pt) | Moduladores de receptores de glucocorticóides | |
| PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
| AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |